Exacerbations in COPD: What’s the risk?
How does an exacerbation affect patient quality of life and lung function?
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket
83% of COPD Triple Therapy patients in UK are managing once and twice daily dosing concurrently1
INTREPID: Trelegy Ellipta vs triple therapy delivered in multiple non Ellipta inhalers. Phase IV, randomised, open label, multicentre effectiveness study.
Trelegy Ellipta prescribing information (PDF)
Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.3
BD, twice daily; BUD, budesonide; CAT, COPD assessment test; FEV1, forced expiratory volume in one second; FF/UMEC/VI, fluticasone furoate, umeclidinium, vilanterol; FOR, formoterol; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; OD, once daily; ARR, absolute risk reduction
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
© 2022 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
Trelegy Ellipta was developed in collaboration with
September 2022 | PM-GB-FVU-WCNT-220001 (V2.0)